Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers
Kelly E. Dooley(Johns Hopkins University), Jeong‐Gun Park(Brigham and Women's Hospital), Richard Hafner(National Institutes of Health), Laura Hovind(Frontier Science & Technology Research Foundation, Inc.), David W. Haas(Meharry Medical College), Jennifer Janik(Hospital of the University of Pennsylvania), Evelyn Hogg(Social and Scientific Systems (United States)), Yoninah Cramer(Harvard University), Constance A. Benson(University of Colorado Health), Mark A. Marzinke(Family Health International 360), Kristine B. Patterson(University of North Carolina at Chapel Hill), Radojka M. Savić(University of California, San Francisco), Susan E. Dorman(Medical University of South Carolina)
Cited by 21
Related Papers
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
|Clinical Infectious Diseases|2016|1.5k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|891
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
|New England Journal of Medicine|2016|768
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
|The Lancet Infectious Diseases|2017|688